Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
The 2025 multigroup consensus guidelines for target delineation of NPC recommend GTVp to CTVp expansion of 0mm (previously 5mm in the 2017 guidelines). What do you do in your practice?
linkinghub.elsevier.com/retrieve/pii/S1470-2045(25)00326-2
Related Questions
How would you manage a presumed radiation induced sarcoma of the head and neck?
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
For a patient with a salivary gland tumor with evidence of local recurrence would you recommend 6 weekly fractions if giving RT alone?
How would the updated results of ECOG 3311 influence your adjuvant RT recommendations for HPV+ OPSCC?
How would you approach a patient with a carotid body tumor and metastasis to the cervical lymph node?
How are you integrating the findings from KEYNOTE-689 into daily practice?
What is the preferred neoadjuvant/adjuvant chemotherapy regimen for HPV-associated nasopharyngeal cancer?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
Would you recommend adjuvant radiation for a patient with head/neck merkel cell carcinoma following a pathologic complete response to neoadjuvant immunotherapy?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?